Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Severe Congenital Adrenal Hyperplasia Presenting as Bilateral Testicular Tumors and Azoospermia in the Third Decade of Life.

Sarfati J, Vatier C, Keller I, Guéchot J, Bellanné-Chantelot C, Christin-Maitre S.

J Endocr Soc. 2018 Jul 4;2(9):997-1000. doi: 10.1210/js.2018-00103. eCollection 2018 Sep 1.

2.

Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification.

Tavarelli M, Sarfati J, Chereau N, Tissier F, Golmard JL, Ghander C, Lussey-Lepoutre C, Trésallet C, Menegaux F, Leenhardt L, Buffet C.

Thyroid. 2017 Jun;27(6):778-786. doi: 10.1089/thy.2016.0512. Epub 2017 Apr 24.

PMID:
28351220
3.

Pituitary Adenoma Recurrence Suspected on Central Hyperthyroidism Despite Empty Sella and Confirmed by 68Ga-DOTA-TOC PET/CT.

Gauthé M, Sarfati J, Bourcigaux N, Christin-Maitre S, Talbot JN, Montravers F.

Clin Nucl Med. 2017 Jun;42(6):454-455. doi: 10.1097/RLU.0000000000001628.

PMID:
28263215
4.

Hypertrophic Osteoarthropathy and Follicular Thyroid Cancer: A Rare Paraneoplastic Syndrome.

Tavarelli M, Sarfati J, De Gennes C, Haroche J, Buffet C, Ghander C, Simon JM, Ménégaux F, Leenhardt L.

Eur Thyroid J. 2015 Dec;4(4):266-70. doi: 10.1159/000437052. Epub 2015 Aug 14.

5.

Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life.

Sarfati J, Bouvattier C, Bry-Gauillard H, Cartes A, Bouligand J, Young J.

Orphanet J Rare Dis. 2015 Jun 9;10:71. doi: 10.1186/s13023-015-0287-9.

6.

Sex steroids, precursors, and metabolite deficiencies in men with isolated hypogonadotropic hypogonadism and panhypopituitarism: a GCMS-based comparative study.

Giton F, Trabado S, Maione L, Sarfati J, Le Bouc Y, Brailly-Tabard S, Fiet J, Young J.

J Clin Endocrinol Metab. 2015 Feb;100(2):E292-6. doi: 10.1210/jc.2014-2658. Epub 2014 Nov 13.

PMID:
25393641
7.

Pituitary stalk interruption and olfactory bulbs aplasia/hypoplasia in a man with Kallmann syndrome and reversible gonadotrope and somatotrope deficiencies.

Sarfati J, Saveanu A, Young J.

Endocrine. 2015 Aug;49(3):865-6. doi: 10.1007/s12020-014-0475-8. Epub 2014 Nov 9. No abstract available.

PMID:
25381604
8.

The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients.

Marcos S, Sarfati J, Leroy C, Fouveaut C, Parent P, Metz C, Wolczynski S, Gérard M, Bieth E, Kurtz F, Verier-Mine O, Perrin L, Archambeaud F, Cabrol S, Rodien P, Hove H, Prescott T, Lacombe D, Christin-Maitre S, Touraine P, Hieronimus S, Dewailly D, Young J, Pugeat M, Hardelin JP, Dodé C.

J Clin Endocrinol Metab. 2014 Oct;99(10):E2138-43. doi: 10.1210/jc.2014-2110. Epub 2014 Jul 31. Erratum in: J Clin Endocrinol Metab. 2015 Jan;100(1):317.

PMID:
25077900
9.

Congenital hypogonadotropic hypogonadism and Kallmann syndrome as models for studying hormonal regulation of human testicular endocrine functions.

Trabado S, Lamothe S, Maione L, Bouvattier C, Sarfati J, Brailly-Tabard S, Young J.

Ann Endocrinol (Paris). 2014 May;75(2):79-87. doi: 10.1016/j.ando.2014.04.011. Epub 2014 May 9. Review.

PMID:
24815726
10.

Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients.

Trabado S, Maione L, Bry-Gauillard H, Affres H, Salenave S, Sarfati J, Bouvattier C, Delemer B, Chanson P, Le Bouc Y, Brailly-Tabard S, Young J.

J Clin Endocrinol Metab. 2014 Feb;99(2):E268-75. doi: 10.1210/jc.2013-2288. Epub 2013 Nov 15.

PMID:
24243640
11.

Greater prevalence of PROKR2 mutations in Kallmann syndrome patients from the Maghreb than in European patients.

Sarfati J, Fouveaut C, Leroy C, Jeanpierre M, Hardelin JP, Dodé C.

Eur J Endocrinol. 2013 Oct 21;169(6):805-9. doi: 10.1530/EJE-13-0419. Print 2013 Dec.

PMID:
24031091
12.

SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development.

Young J, Metay C, Bouligand J, Tou B, Francou B, Maione L, Tosca L, Sarfati J, Brioude F, Esteva B, Briand-Suleau A, Brisset S, Goossens M, Tachdjian G, Guiochon-Mantel A.

Hum Reprod. 2012 May;27(5):1460-5. doi: 10.1093/humrep/des022. Epub 2012 Mar 12.

PMID:
22416012
13.

Impact of clinical, hormonal, radiological, and immunohistochemical studies on the diagnosis of postmenopausal hyperandrogenism.

Sarfati J, Bachelot A, Coussieu C, Meduri G, Touraine P; Study Group Hyperandrogenism in Postmenopausal Women.

Eur J Endocrinol. 2011 Nov;165(5):779-88. doi: 10.1530/EJE-11-0542. Epub 2011 Sep 6.

PMID:
21896622
14.

Kallmann syndrome caused by mutations in the PROK2 and PROKR2 genes: pathophysiology and genotype-phenotype correlations.

Sarfati J, Dodé C, Young J.

Front Horm Res. 2010;39:121-32. doi: 10.1159/000312698. Epub 2010 Apr 8. Review.

PMID:
20389090
15.

A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes.

Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Piñero A, Wolczynski S, Brailly-Tabard S, Bidet M, Ramos-Arroyo M, Mathieu M, Lienhardt-Roussie A, Morgan G, Turki Z, Bremont C, Lespinasse J, Du Boullay H, Chabbert-Buffet N, Jacquemont S, Reach G, De Talence N, Tonella P, Conrad B, Despert F, Delobel B, Brue T, Bouvattier C, Cabrol S, Pugeat M, Murat A, Bouchard P, Hardelin JP, Dodé C, Young J.

J Clin Endocrinol Metab. 2010 Feb;95(2):659-69. doi: 10.1210/jc.2009-0843. Epub 2009 Dec 18.

PMID:
20022991
16.

Impact of combined and progestogen-only contraceptives on bone mineral density.

Sarfati J, de Vernejoul MC.

Joint Bone Spine. 2009 Mar;76(2):134-8. doi: 10.1016/j.jbspin.2008.09.014. Epub 2009 Feb 1. Review.

PMID:
19181558

Supplemental Content

Loading ...
Support Center